{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:51:52Z","timestamp":1760205112660,"version":"3.41.2"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SOT recipients are more vulnerable to infections with antimicrobial\u2010resistant organisms, and therefore, it may be useful for transplant centers to create transplant\u2010specific antibiograms to direct empirical antimicrobial regimens and monitor trends in antimicrobial resistance. SOT\u2010specific antibiograms were created using antimicrobial susceptibility data on isolates from 2012 to 2018 at The Hospital for Sick Children, Toronto, Ontario, Canada. The CLSI guidelines were followed to generate the antibiograms except that results from 2\u00a0years of data were pooled on a rolling basis to achieve larger sample sizes. The 3 most frequent organisms in one analysis period of the SOT antibiogram were\u00a0<jats:italic>Escherichia coli<\/jats:italic> (average sample size \u00b1standard deviation; n\u00a0=\u00a028.7\u00a0\u00b1\u00a03.8), <jats:italic>Staphylococcus aureus<\/jats:italic> (n\u00a0=\u00a027.8\u00a0\u00b1\u00a05.0), and <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (non\u2010CF) (n\u00a0=\u00a019.8\u00a0\u00b1\u00a08.8). For <jats:italic>E.coli<\/jats:italic>, susceptibilities in the SOT antibiogram were significantly lower than those in the hospital\u2010wide antibiogram in 2017\u20132018 for ampicillin (27% vs 47%;\u00a0<jats:italic>p<\/jats:italic>\u00a0=\u00a0.014), piperacillin\/tazobactam (55% vs 88%;\u00a0<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001), cefotaxime (59% vs 89%;\u00a0<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001), ciprofloxacin (71% vs 88%;\u00a0<jats:italic>p<\/jats:italic>\u00a0=\u00a0.007), and trimethoprim\u2010sulfamethoxazole (41% vs 69%;\u00a0<jats:italic>p<\/jats:italic>\u00a0=\u00a0.001), but not significantly different for aminoglycosides and meropenem.\u00a0In the SOT antibiogram of <jats:italic>E<\/jats:italic>. <jats:italic>coli<\/jats:italic>, decreased susceptibility trend was confirmed in some antibiotics, including piperacillin\/tazobactam (83% in 2012\u20132013 vs 55% in 2017\u20132018). At our center, the solid organ transplant\u2013specific antibiogram revealed important differences in\u00a0<jats:italic>E<\/jats:italic>. <jats:italic>coli<\/jats:italic>\u00a0susceptibilities and trends in antimicrobial resistance. Developing a SOT antibiogram will assist in revising and improving empiric treatment guidelines as well as monitoring antimicrobial resistance in this population.<\/jats:p>","DOI":"10.1111\/petr.13980","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T16:53:33Z","timestamp":1612457613000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Solid organ transplant\u2013specific antibiogram in a tertiary pediatric hospital in Canada"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-066X","authenticated-orcid":false,"given":"Taito","family":"Kitano","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Paediatric Medicine Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Science","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Paediatric Medicine Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadya","family":"Nalli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Timberlake","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-7731","authenticated-orcid":false,"given":"Upton","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Paediatric Medicine Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-0799","authenticated-orcid":false,"given":"Chia Wei","family":"Teoh","sequence":"additional","affiliation":[{"name":"Division of Nephrology Department of Paediatric Medicine Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Campigotto","sequence":"additional","affiliation":[{"name":"Department of Paediatric Laboratory Medicine Hospital for Sick Children Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt363"},{"key":"e_1_2_11_3_1","unstructured":"World Health Organization. 2018.Global antimicrobial resistance surveillance system (GLASS) report. World Health Organization Geneva.https:\/\/www.who.int\/glass\/resources\/publications\/early\u2010implementation\u2010report\/en\/. Accessed June 13 2020."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.06.061"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00421.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2018.04.004"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.08.018"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.07.080"},{"volume-title":"Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data","year":"2014","author":"Clinical and Laboratory Standards Institute","key":"e_1_2_11_9_1"},{"key":"e_1_2_11_10_1","unstructured":"Agency for Healthcare Research and Quality.Comprehensive Antibiogram Toolkit: Phase 2 Antibiogram Specifications;2014. AHRQ Antibiogram Specifications Phase 2. Agency for Healthcare Research and Quality Rockville MD.https:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/professionals\/quality\u2010patient\u2010safety\/patient\u2010safety\u2010resources\/resources\/nh\u2010aspguide\/module2\/toolkit2\/phase2\/abspecs\u2010ph2.pdf. Accessed June 27 2020."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/505921"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.133.10.1041"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn384"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.08.009"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02992-15"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13595"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2008.076"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02664.x"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.13980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/petr.13980","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/petr.13980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:21:01Z","timestamp":1693574461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/petr.13980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/petr.13980"],"URL":"https:\/\/doi.org\/10.1111\/petr.13980","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"type":"print","value":"1397-3142"},{"type":"electronic","value":"1399-3046"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"2020-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13980"}}